Disseminated Cryptococcosis Following Eculizumab Therapy: Insight Into Pathogenesis.
Olivier LortholaryCarine El-SissyJérémie LeporrierSarah Sze Wah WongEric DannaouiVéronique Fremeaux-BacchiVishukumar AimaniandaPublished in: Open forum infectious diseases (2023)
Eculizumab, a recombinant humanized monoclonal antibody (mAb), is used for the treatment of patients (both adults and children) with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. This mAb binds to complement protein 5 (C5), thereby inhibiting its cleavage. On the other hand, one of the C5 cleavage products, C5a, is a potent anaphylatoxin with proinflammatory properties, involved in antimicrobial surveillance. Administration of eculizumab has been reported to make patients more susceptible to infection by encapsulated bacteria. Here, we are reporting an adult case of disseminated infection due to the encapsulated yeast Cryptococcus neoformans following eculizumab therapy and discuss its pathogenesis.
Keyphrases
- monoclonal antibody
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- public health
- ejection fraction
- blood pressure
- obstructive sleep apnea
- atrial fibrillation
- young adults
- peritoneal dialysis
- stem cells
- anti inflammatory
- amino acid
- patient reported
- adverse drug
- binding protein
- small molecule
- sleep apnea